REPLY
19.9.2023 09:31:27 CEST | Business Wire | Press release
Reply, a global systems integrator and consulting firm and Oracle Cloud Managed Service Provider, has received 4 Oracle Partner awards in recognition of its capabilities to deliver pioneering solutions, drive business value and customers success. The EMEA Cluster Partner Awards, announced at the Oracle EMEA Partner Appreciation Reception during Oracle CloudWorld in Las Vegas, have been awarded to the Reply companies specialized on Oracle technologies; Healthy Reply, Nimbus Reply and Red Reply.
The awards celebrate partners that foster innovation, accelerate business growth and create value to enable success for customers through technology integration and services built on Oracle Cloud Application, Oracle Cloud Infrastructure and Oracle Database technology. The Reply companies, focused on Oracle Cloud Infrastructure solutions and experts in end-to-end Oracle solutions, received the following EMEA Cluster Partner Awards:
- 2023 Customer Success Partner of Year – Europe South Tech / Cloud has been given to Nimbus Reply for the high customer satisfaction they have earned by empowering customers with innovative multi-cloud solutions. These resulted in a reduction of operational costs, an increase in application performance and improvements in system scalability, all while considering critical regulatory requirements.
- 2023 Customer Success Partner of Year – Europe North & East Tech / Cloud has been awarded to Red Reply for their capabilities to increase value to their end customers by streamlining solution implementation and management, improving human capital efficiency, reducing costs, minimizing technical debt, and achieving a measurable return on investment.
- 2023 Business Impact Partner of Year – Europe South Apps / SaaS has been assigned to Healthy Reply for developing exceptional solutions based on Oracle SaaS for the healthcare industry. The solutions developed allow to expedite projects and maximise the benefits of Cloud releases resulting invaluable for clients in managing specific processes and integrating with healthcare national systems.
- 2023 Innovation Partner of Year – Europe North & East Tech / Cloud has been granted to Red Reply for their capabilities to create pioneering solutions that empower customers and support these meeting their business goals and challenges. Red Reply have developed a solution that enables companies to seamlessly migrate their Legacy applications to the Cloud quickly. This rapid migration not only results in immediate cost savings but also enhances the company’s operational efficiency. Additionally, the system allows the transformation of Legacy Applications into Cloud-based Software-as-a-Service (SaaS) through a fully managed service, thus eliminating the need for extensive in-house development resources.
Filippo Rizzante, CTO at Reply, said, “We are delighted to have won these awards that reflect our continuous commitment in delivering cutting-edge Oracle solutions. Our ongoing investments in innovation and research & development, together with the expertise and capabilities of our companies dedicated to Oracle technologies allow us to support our customers better and to get the most from Oracle solutions.”
Reply, Oracle partner since 1997, with its companies dedicated to Oracle technologies, is best in class in Oracle Cloud Computing. With over 1500 certifications Oracle, Reply owns and manages one of the main European centers of competence. Reply is able to combine the full coverage of the entire supply chain, has experience in Oracle application suites, in Oracle technologies and in the main Oracle vertical solutions for the industry.
More information about Reply and Oracle partnership here.
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
Healthy Reply
Healthy Reply is the Reply Group company specialising in telemedicine, telemonitoring and the continuity of social welfare. Healthy Reply collaborates with public and private healthcare institutions and bodies, clinics and hospitals, social and healthcare facilities, insurance companies and banks, convention centres and enterprises, to design customised services that can guarantee continuous care and assistance. Healthy Reply has established strong competencies in Oracle ERPM Cloud solutions and continue to invest in expanding its offerings across all Oracle SaaS solutions.
Nimbus Reply
Nimbus Reply is the Reply Group company specialising in the delivery of Multi-Cloud solutions for the Health and Public Sector market. Composed of specialists with expertise in several Cloud Service Providers, Nimbus Reply promotes the adoption and evolution of the Cloud paradigm in the Public Sector, supporting end-to-end customers in the Journey to Multi-Cloud, in a Cloud Continuum perspective.
Red Reply
Red Reply is the Reply Group company specialising in Oracle Cloud Infrastructure with a focus on IaaS and PaaS solutions and offers Cloud Strategy and Migration, Application Development, Cloud / Application Management and Operations services. Red Reply is an expert in end-to-end Oracle solutions and one of first Oracle Cloud Managed Service Providers (MSP) in Europe. www.red.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230919738958/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom